Skip to main content
Quest Diagnostics

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes

Authors: Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K.

Citation: J Clin Endocrinol Metab. 2021 Jun 30;dgab417. doi: 10.1210/clinem/dgab417. Online ahead of print.

Specialties: Cardiology, Cardiovascular disease, Endocrinology, 

Download key summary

Related content

Test FAQ
NAFLD Fibrosis Score
Publication
Differences in HDL-Bound Apolipoproteins in Patients with Advanced Liver Fibrosis due to Nonalcoholic Fatty Liver Disease
Conference Presentation
Differences in HDL Particle Composition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Liver Fibrosis May Explain Higher Cardiovascular Risk
Conference Presentation
Fasting Intact Insulin by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) as a Predictor of Nonalcoholic Fatty Liver Disease in Pediatric Patients
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.